{"url_path":"/sec/rgnx/8-k/2026-05-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-222768-index.html","accession_number":"0001193125-26-222768","cik":"0001590877","ticker":"RGNX","issuer_name":"REGENXBIO Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-222768-index.html","primary_entity_key":"0001590877","primary_entity_name":"REGENXBIO Inc."},"word_count":132,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nOn May 14, 2026, the Company presented topline and interim data analysis from the pivotal Phase III AFFINITY DUCHENNE® trial of RGX-202. A copy of the presentation materials is available on the “Presentations and Publications” section of the Company’s website at www.regenxbio.com.\n\nThe information in Item 7.01 of this Current Report on Form 8‑K and the presentation materials on the Company’s website shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}